Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Paisan Ruamviboonsuk, EURETINA 2021: Artificial Intelligence in Ophthalmology

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 20th 2021

It was a pleasure to speak with Paisan Ruamviboonsuk (Rajavithi Hospital, Bangkok, Thailand) about his views on artificial intelligence in ophthalmology, specifically for diagnosis and screening for polypoidal choroidal vasculopathy.

Questions

  1. Could you give us a brief overview of your research in artificial intelligence (AI) in ophthalmology? (00:18)
  2. What is the potential of AI in the diagnosis and screening for polypoidal choroidal vasculopathy (PCV)? (01:13)
  3. What are the major challenges in developing AI-based tools in this application? (03:02)

Speaker Disclosure: Paisan Ruamviboonsuk has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of EURETINA 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup